AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
isoxicam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| anti-inflammatory, isoxicam derivatives | 1509 | 34552-84-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 17.04 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 97 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.19 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 0.07 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.04 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 33 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 0.03 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -0.289 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 2.559 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 117.220 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 3.963 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 7.160 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 9.620 | % | High | 1 |
| herg | hERG pIC50 | 3.991 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 3.365 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 2.979 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 1.190 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,KIT,MAP3K21,MAP3K7,MAP4K1,MAPK7,MAPK9,MARK4,MTOR,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1 | 47 | |||
| kinase-selectivity-class | ACVR2A,AURKB,AXL,BRAF,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,GRK2,MAP2K6,MAPK12,MAPK7,MARK4,PRKDC,SIK2,STK33,TEK,TTK | 19 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 7.096 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 10 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 10.430 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 1.306 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 0 | Moderate | 0.67 | |
| pppb | Pig plasma protein binding (% unbound) | 4.630 | % | High | 1 |
| rat-kpuu-brain | Rat brain Kpuu | 0.594 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 3.214 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 93.900 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 1.530 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 968.278 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 1, 1983 | YEAR INTRODUCED |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D000893 | Anti-Inflammatory Agents |
| MeSH PA | D000894 | Anti-Inflammatory Agents, Non-Steroidal |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018501 | Antirheumatic Agents |
| MeSH PA | D018689 | Sensory System Agents |
| MeSH PA | D018712 | Analgesics, Non-Narcotic |
| CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory drug |
| CHEBI has role | CHEBI:35842 | antirheumatic drug |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.97 | acidic |
| pKa2 | 7.73 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Prostaglandin G/H synthase 2 | Enzyme | IC50 | 5.20 | WOMBAT-PK | |||||
| Prostaglandin G/H synthase 1 | Enzyme | IC50 | 5.10 | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| D04639 | KEGG_DRUG |
| C0064104 | UMLSCUI |
| CHEBI:76163 | CHEBI |
| ICD | PDB_CHEM_ID |
| CHEMBL53292 | ChEMBL_ID |
| DB08942 | DRUGBANK_ID |
| C013580 | MESH_SUPPLEMENTAL_RECORD_UI |
| 54677972 | PUBCHEM_CID |
| 3435 | INN_ID |
| 8XU734C4NG | UNII |
| 008283 | NDDF |
Pharmaceutical products:
None